Abstract: The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.

Abstract: A method for identifying cognate pairs of a ligand species and a receptor species includes co-compartmentalizing ligand species and receptor species, forming a set of microreactors, each microreactor including a ligand species and preferably a receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when a ligand species and receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species.

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

Abstract: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: A pulley for installation in a pulley mechanism of a Jacquard machine has a shaft, a housing having two flank bodies, which are provided to fasten the shaft, so that this shaft extends substantially between the flank bodies, and a pulley wheel, which is provided to be arranged between the two flank bodies so as to be directly rotatable around the shaft. The shaft, prior to assembly of the pulley, is provided with cavities and/or projecting portions for the post-assembly axial securement of the flank bodies in both axial directions.

Abstract: Systems for management of a large computing cluster. A set of computing nodes within the cluster are identified. The identified nodes are to be reimaged with an operating system image and parameters. One or more reimaging algorithms in the form of computer code are stored in a networked storage device within a storage pool that comprises the networked storage device and a plurality of local storage devices that correspond to respective individual ones of the set of computing nodes. An agent that can execute the reimaging algorithm code is configured to run on any one of the set of computing nodes, wherein the agent is further configured to retrieve reimaging data from a storage device that is within the storage pool. An agent running on a leader node initiates reimaging of a second node. The second node initiates reimaging of a third node. The third node reimages the leader node.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use to thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: Systems for management of a large computing cluster. A set of computing nodes within the cluster are identified. The identified nodes are to be reimaged with an operating system image and parameters. One or more reimaging algorithms in the form of computer code are stored in a networked storage device within a storage pool that comprises the networked storage device and a plurality of local storage devices that correspond to respective individual ones of the set of computing nodes. An agent that can execute the reimaging algorithm code is configured to run on any one of the set of computing nodes, wherein the agent is further configured to retrieve reimaging data from a storage device that is within the storage pool. An agent running on a leader node initiates reimaging of a second node. The second node initiates reimaging of a third node. The third node reimages the leader node.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalizing two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalized into the microcapsules.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: A pulley (1) for installation in a pulley mechanism of a Jacquard machine, comprising a shaft (3); a housing (4), comprising two flank bodies (5), which are provided to fasten the shaft (3), so that this shaft (3) extends substantially between the flank bodies (5); and a pulley wheel (6), which is provided to be arranged between the two flank bodies (5) so as to be directly rotatable around the shaft (3); wherein the shaft (3), prior to assembly of the pulley (1), is provided with cavities (7, 10, 11) and/or projecting portions for the post-assembly axial securement of the flank bodies (5) in both axial directions.

Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control, The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.

Abstract: A module suitable for installation in a jacquard machine, comprising at least one partition provided for guiding shed-forming elements, wherein the shed-forming elements comprise at least one anchor element which is configured to be held pressed against a contact profile of the jacquard machine when the module has been installed in the jacquard machine, wherein said anchor element is displaceable from a first position of use to a second removal position for removing the module from the jacquard machine.

Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising of the steps of: (a) compartmentalizing genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having a desired activity. The invention enables the in vitro evolution of nucleic acids by repeated mutagenesis and iterative applications of the method of the invention.

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.